AMRX - Amneal joins hands with Orion to commercialize generic products in Europe and more countries

• Amneal Pharmaceuticals ( NYSE: AMRX ) has signed a long-term license agreement with Orion Corporation to commercialize a number of complex generic products.
• Under the partnership agreement, Orion is Amneal’s exclusive partner to bring its portfolio of complex generic programs to most parts of Europe as well as in Australia and New Zealand.
• Chirag Patel and Chintu Patel, Amneal Co-Chief Executive Officers, stated, “International expansion is a key strategic priority for Amneal and today’s announcement demonstrates our commitment to execute on that. As a company, we are extremely focused on finding partners who share our same values, ethics and ambitions, and we truly could not have found a better European partner than Orion. We are excited to bring our medicines to the second largest global pharmaceutical market, and we hope that today is only the beginning of our work together.”

For further details see: